<DOC>
	<DOCNO>NCT00105209</DOCNO>
	<brief_summary>Rationale : Idiopathic pulmonary arterial hypertension ( IPAH ) characterize situ thrombosis increase thromboxane A2 ( Tx-M ) synthesis . While may attributable abnormal platelet function , study anti-platelet therapy IPAH . Objectives : The purpose study assess effect aspirin ( ASA ) clopidogrel platelet function eicosanoid metabolism patient IPAH .</brief_summary>
	<brief_title>A Study Aspirin Clopidogrel Patients With Idiopathic Pulmonary Arterial Hypertension</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled crossover study aspirin 81 mg daily clopidogrel 75 mg daily . Platelet function assess plasma P-selectin level aggregometry exposure adenosine diphosphate , arachidonic acid , collagen . We assess serum level thromboxane B2 urinary metabolite thromboxane A2 prostaglandin I2 ( Tx-M PGI-M , respectively ) .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Diagnosis IPAH ≥ 18 year age NYHA functional class I , II , III Clinical stability ( i.e. , without change pulmonary arterial hypertension medical regimen within one month prior enrollment ) . Other form PAH A contraindication ASA clopidogrel Thrombocytopenia ( define platelet count ≤ 75,000 ) History intracranial hemorrhage chronic thromboembolic disease Renal failure Inability unwillingness avoid nonsteroidal antiinflammatory agent , ASA , warfarin use duration trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2005</verification_date>
	<keyword>Platelets</keyword>
</DOC>